Related Experiment Videos
Effect of recombinant human erythropoietin in preterm infants
N Krallis1, V Cholevas, A Mavridis
1Child Health Department, Neonatology Clinic, University of Ioannina, Medical School, Greece.
Insights
Recombinant human erythropoietin (rHuEpo) treatment in premature infants showed improved iron status markers, indicated by higher serum soluble transferrin receptors (sTfR). This suggests rHuEpo may positively impact iron metabolism in preterm neonates.
Area of Science:
- Neonatal Medicine
- Hematology
- Pharmacology
Background:
- Premature infants often experience iron deficiency due to limited iron stores and increased demands.
- Erythropoietin is a hormone that stimulates red blood cell production and may influence iron metabolism.
Purpose of the Study:
- To investigate the effect of recombinant human erythropoietin (rHuEpo) on iron status and red blood cell phosphate metabolites in premature infants.
- To assess the correlation between rHuEpo administration and specific hematological indices.
Main Methods:
- A randomized controlled trial involving 25 premature infants treated with rHuEpo and 23 controls.
- Subcutaneous administration of rHuEpo (300 u/kg) three times weekly for 6 weeks.
- Monthly monitoring of hematological indices, serum phosphate, and red blood cell phosphate metabolites up to 12 months.
Main Results:
- Serum soluble transferrin receptors (sTfR) levels correlated significantly with rHuEpo treatment (p<0.05).
- The ratio of sTfR to log (ferritin) was significantly higher in the rHuEpo group (p<0.001), indicating improved iron availability.
- No significant effects on intracellular phosphate metabolites were observed; RBC 2,3-DPG levels appeared adequate.
Conclusions:
- Subcutaneous rHuEpo administration in premature infants appears to improve iron status markers.
- rHuEpo may positively influence iron metabolism and availability in preterm neonates.
- Further research is warranted to fully elucidate the impact of rHuEpo on iron homeostasis in this population.
Abstract:
Twenty-five premature infants (mean gestational age+/-SD, 31.4+/-1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature infants with a mean gestational age of 32.2+/-2.3 weeks who did not receive rHuEpo. Haematological indices, haemoglobin and serum phosphate (Pi), and red blood cell (RBC) phosphate metabolites (ATP, 2,3-DPG, RBCPi) were tested monthly until the 6th month and thereafter at the 9th and 12th months of life. The level of serum soluble transferrin receptors (sTfR) correlated significantly with rHuEpo (p<0.05). The ratio of sTfR to log (ferritin) was significantly higher (p<0.001) in the infants treated with rHuEpo than the controls. Intracellular organic and inorganic Pi changes were not affected by the Epo administration. The RBC 2,3-DPG seemed adequate in infants receiving rHuEpo.